Jörg Hanrieder
@neurochem.bsky.social
Professor of Neurochemistry, University of Gothenburg and University College London
https://www.gu.se/en/research/analytical-neurochemistry
https://www.gu.se/en/research/analytical-neurochemistry
Happy to share our latest work published today in @natcomms.nature.com
We leverage #ai enhanced microscopy guided #maldi #msimaging to delineate #amyloid plaque polymorphism in #Alzheimers Fantastic collaboration with @michaelschoell.bsky.social and @tammarynlashley.bsky.social
rdcu.be/ejcHj
We leverage #ai enhanced microscopy guided #maldi #msimaging to delineate #amyloid plaque polymorphism in #Alzheimers Fantastic collaboration with @michaelschoell.bsky.social and @tammarynlashley.bsky.social
rdcu.be/ejcHj
Chemical imaging delineates Aβ plaque polymorphism across the Alzheimer’s disease spectrum
Nature Communications - Deep learning enhanced chemical imaging delineated polymorphic Aβ plaques in situ. Cored plaques were associated with increased Aβ1-40 and 3pE-42 deposition. A...
rdcu.be
April 25, 2025 at 6:10 PM
Happy to share our latest work published today in @natcomms.nature.com
We leverage #ai enhanced microscopy guided #maldi #msimaging to delineate #amyloid plaque polymorphism in #Alzheimers Fantastic collaboration with @michaelschoell.bsky.social and @tammarynlashley.bsky.social
rdcu.be/ejcHj
We leverage #ai enhanced microscopy guided #maldi #msimaging to delineate #amyloid plaque polymorphism in #Alzheimers Fantastic collaboration with @michaelschoell.bsky.social and @tammarynlashley.bsky.social
rdcu.be/ejcHj
Reposted by Jörg Hanrieder
📣 Breaking News
European Medicines Agency has decided to approve lecanemab for early Alzheimer’s with some restrictions.
This follows and mirrors a positive MHRA decision earlier in the year.
These treatments are modest at best but do represent some progress were making in Alzheimer’s research.
European Medicines Agency has decided to approve lecanemab for early Alzheimer’s with some restrictions.
This follows and mirrors a positive MHRA decision earlier in the year.
These treatments are modest at best but do represent some progress were making in Alzheimer’s research.
November 14, 2024 at 5:18 PM
📣 Breaking News
European Medicines Agency has decided to approve lecanemab for early Alzheimer’s with some restrictions.
This follows and mirrors a positive MHRA decision earlier in the year.
These treatments are modest at best but do represent some progress were making in Alzheimer’s research.
European Medicines Agency has decided to approve lecanemab for early Alzheimer’s with some restrictions.
This follows and mirrors a positive MHRA decision earlier in the year.
These treatments are modest at best but do represent some progress were making in Alzheimer’s research.
Reposted by Jörg Hanrieder
I have created a starter pack of UCL people and accounts on here. Please share and if you are currently affiliated to UCL, please let me know if you would like to be added. go.bsky.app/F2fnEWt
November 13, 2024 at 8:16 AM
I have created a starter pack of UCL people and accounts on here. Please share and if you are currently affiliated to UCL, please let me know if you would like to be added. go.bsky.app/F2fnEWt